Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 15 hours agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 4 days agoPatients will receive Keytruda or Keytruda plus the vaccine after bladder or kidney removal. Bladder...
NCCN 2024 Annual Conference Shares Cancer Care Updates for Practical, Immediate Use in Practice
Newswise· 2 weeks ago“The NCCN Annual Conference has always been one of my favorite events, because it is an opportunity...
Signs and Symptoms of Kidney Cancer
Health via Yahoo News· 5 days agoIn fact, kidney cancer is often found accidentally during a routine physical or imaging exam, such as an X-ray or MRI. There are three main types of kidney cancers ...
Yellow Nail Syndrome: What to Know
Verywell Health via Yahoo News· 7 days agoCertain forms of cancer: Rarely, it has been associated with multiple myeloma (bone marrow cancer), lung cancer, breast cancer ...
Janux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at Jonestrading
ETF DAILY NEWS· 7 days agoWilliam Blair reiterated an outperform rating on shares of Janux Therapeutics in a research note on Tuesday, February 27th. Bank of America increased their target price on Janux Therapeutics ...
Immunotherapy After Kidney Cancer Surgery Improves Overall Survival
Technology Networks· 6 days agoTreatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall...
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $52.65
ETF DAILY NEWS· 7 days agoJanux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $52.65, but opened at $51.05. Janux Therapeutics ...
AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class
FierceBiotech· 2 weeks agoIL-2 medicines have shown the ability to kill tumors. Synthekine is hoping to avoid activating...
Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) CEO Sells 26,716 Shares of Stock
ETF DAILY NEWS· 2 weeks agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) CEO John Oyler sold 26,716 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price ...
